Gritstone Bio, INC 8-K filings

Gritstone Bio, currently undergoing Chapter 11 bankruptcy, has filed its monthly operating report (MOR) for December 2024 with the U.S. Bankruptcy Court for the District of Delaware.

Gritstone Bio has finalized the sale of substantially all of its assets to Seattle Project Corp. for $21.25 million in cash, concluding its Chapter 11 bankruptcy proceedings.

Gritstone Bio has reached agreements to sell its assets for approximately $21.25 million in cash, plus credit bids, following a bankruptcy auction.

Gritstone Bio has filed its monthly operating report for October 2024, detailing its financial status while under Chapter 11 bankruptcy protection.

Gritstone Bio has entered into a debtor-in-possession financing agreement for up to $25 million to support operations during its Chapter 11 bankruptcy.

Gritstone Bio is reducing its workforce by approximately 19% and will be delisted from the Nasdaq stock market following its Chapter 11 bankruptcy filing.

Gritstone Bio has voluntarily filed for Chapter 11 bankruptcy to restructure its finances and continue its strategic alternatives process.

Gritstone Bio's personalized cancer vaccine, GRANITE, shows a potential benefit in progression-free survival for patients with metastatic colorectal cancer, particularly those with low disease burden.

Gritstone Bio announced encouraging preliminary Phase 2 data for its personalized neoantigen vaccine, GRANITE, in metastatic colorectal cancer, along with second quarter financial results and corporate updates.

Gritstone Bio has been notified by Nasdaq that it no longer meets the minimum bid price requirement for continued listing, as its stock price has fallen below $1.00 for 30 consecutive days.

Gritstone Bio held its 2024 annual meeting, electing directors, ratifying the accounting firm, and approving executive compensation on an advisory basis.

Gritstone Bio announced encouraging preliminary Phase 2 results for its GRANITE cancer vaccine, along with a $32.5 million capital raise and updates on other clinical programs.

Gritstone Bio's board of directors sees a resignation and a new appointment, with a new director set to chair the Audit Committee.

Gritstone Bio has entered into an underwriting agreement to sell shares of common stock and warrants, expecting to raise approximately $32.5 million.

Gritstone Bio reported encouraging preliminary progression-free survival data from its Phase 2 study of the GRANITE cancer vaccine in combination with immune checkpoint blockade for metastatic colorectal cancer.

Gritstone Bio announced its 2023 financial results, provided updates on its clinical programs, and disclosed a 40% workforce reduction to preserve capital.

Gritstone Bio is reducing its workforce by approximately 40% to lower costs and conserve capital.

Gritstone Bio has postponed its Phase 2b clinical trial for its COVID-19 vaccine to the fall of 2024 and estimates its cash runway will extend into the third quarter of 2024.